Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00255450 · ClinicalTrials.gov registry record · Phase 3
A Crossover Safety Study of Ferumoxytol Versus Placebo
A Phase 3 study, sponsored by AMAG Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 750
- Enrollment target
NCT00255450: Completed Phase 3 study, sponsored by AMAG Pharmaceuticals.
NCT00255450 is a Phase 3 study that has completed, run by AMAG Pharmaceuticals. The registered enrollment target is 750 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00255450, a Phase 3 study, has completed, sponsored by AMAG Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 750 participants
- Enrollment target
Study Summary
This crossover safety study will evaluate the safety of a single dose of ferumoxytol compared to placebo in patients with chronic kidney disease.
Interventions
- DRUG ferumoxytol or placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
What the finished NCT00255450 record still lists
NCT00255450 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which ferumoxytol or placebo is the first listed.
NCT00255450 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00255450 about?
NCT00255450 is a clinical study titled "A Crossover Safety Study of Ferumoxytol Versus Placebo". This crossover safety study will evaluate the safety of a single dose of ferumoxytol compared to placebo in patients with chronic kidney disease.
What is the current status of trial NCT00255450?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 2005-01. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00255450?
The interventions under investigation include: ferumoxytol or placebo (DRUG).
Who is sponsoring clinical trial NCT00255450?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00255450's enrollment target sits among peer trials
750 464th of 2000 higher than 1,529 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia